Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase III Efficacy Still Unproven, Pimavanserin Bags Acadia Deal With Biovail

This article was originally published in The Pink Sheet Daily

Executive Summary

First of two Phase III studies in Parkinson’s disease psychosis is set to yield data in the third quarter.

You may also be interested in...



Acadia Now Has The Cash To Finish Phase III On Its Own

After announcing promising Phase III data in late November, Acadia Pharmaceuticals conducted a private placement of nearly 20 million shares that will net the company $86.4 million in funds to continue running its Phase III program for pimavanserin in Parkinson’s disease psychosis.

Biovail Presses Forward With CNS Agenda

Canadian drug maker is planning to launch Staccato loxapine and embark on an ambitious clinical program for pimavanserin in 2011.

Biovail Presses Forward With CNS Agenda

Canadian drug maker is planning to launch Staccato loxapine and embark on an ambitious clinical program for pimavanserin in 2011.

Related Content

Topics

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel